US and UK Forge Deal to Adjust Drug Pricing and Boost Pharmaceutical Investment

The United States and United Kingdom have finalized an agreement to change how Britain pays for brand-name medicines. The deal aims to increase pharmaceutical industry investment in the UK by adjusting its drug pricing system. Under the new terms, the UK government will raise the net price it pays for new branded medicines by 25%. It will also lower the mandatory repayment rate from drug companies to the National Health Service (NHS). This repayment, part of a voluntary pricing scheme, will drop to 15% starting in 2026. The current rate is higher but was not specified in the announcement. Officials state the changes balance fair prices for the NHS with better returns for drug developers. The goal is to make the UK a more attractive market for launching new treatments.